BerGenBio

Our CEO, Martin Olin, comments on today’s Q1 2022 results. You can read the report in full here: ow.ly/M3Mp50Jgjru #FinancialResults #BGBIO

Today we announced our Q1 2022 results. A presentation by BerGenBio’s senior management team will take place today at 10 am CEST - watch the webcast here: ow.ly/K3Sb50JgaEI Read the full PR here: ow.ly/lEXb50JgaEL #FinancialResults

We’re pleased to announce complete data analysis from the #ACCORD2 phase II study of #bemcentinib in combination with #SoC therapy in hospitalized #COVID19 patients. The primary endpoint of improved clinical response was met. Read the full release here: bergenbio.com/bergenbio-anno…

We’re presenting data from our BGBC020 clinical trial in hospitalised #COVID19 patients today at #ECCMID2022. Read the full release here: tools.eurolandir.com/tools/P…

Yesterday we announced a publication in Cell Reports Medicine on #AXL as a driver of immune suppression in STK11/LKB1 mutated NSCLC. STK11 is associated with poor treatment outcomes in NSCLC. There are currently no STK11-targeted therapies . Link: bit.ly/3KRhDgq

BerGenBio’s CEO, Martin Olin, comments on today’s Q4 and FY 2021 results. You can view the report in full here: bergenbio.com/wp-content/upl… #financialresults #BGBIO

Today we announced our Q4 and FY 2021 #results. A presentation by BerGenBio’s senior management team will take place today at 10am CET. If you would like to watch the live webcast, follow this link: bit.ly/3sJS0GU Read the press release here: bit.ly/3gR2QVO

We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the @EU_SolidAct trial. Read the release here: bergenbio.com/investors/stoc… #AXL

This morning BerGenBio announced a license agreement with @UTSWNews The exclusive license is related to the treatment of Non-Small Cell Cancer (NSCLC) patients with #STK11 mutations and supports the Company’s existing IP position. Read here: bergenbio.com/bergenbio-anno…

CEO Martin Olin comments on BerGenBio’s Q3 2021 results, out today. You can view the report in full here: bergenbio.com/wp-content/upl… #financialresults #BGBIO